tyrosine kinase inhibitor

Open Access
Comparative Analysis of Immune-based Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma
YUTA MUKAE, KOJIRO OHBA, HIROMI NAKANISHI, MASAHARU OKI, KEN KAWADA, TSUYOSHI MATSUDA, KENSUKE MITSUNARI, TOMOHIRO MATSUO, YASUSHI MOCHIZUKI and RYOICHI IMAMURA

In Vivo January 2026, 40 (1) 389-397; DOI: https://doi.org/10.21873/invivo.14203
Open Access
Comparison of the Use of Immune Checkpoint Inhibitor/Tyrosine Kinase Inhibitor and Tyrosine Kinase Inhibitor Alone for Patients With Low Risk Metastatic Renal Cell Carcinoma
MASAHARU OKI, KOJIRO OHBA, YUTA MUKAE, TSUYOSHI MATSUDA, HIROMI NAKANISHI, KENSUKE MITSUNARI, TOMOHIRO MATSUO, YASUSHI MOCHIZUKI and RYOICHI IMAMURA

In Vivo November 2025, 39 (6) 3445-3452; DOI: https://doi.org/10.21873/invivo.14142
You have access
Sunitinib Treatment-elicited Distinct Tumor Microenvironment Dramatically Compensated the Reduction of Myeloid-derived Suppressor Cells
SHENG-YUNG FU, CHUN-CHIEH WANG, FANG-HSIN CHEN, CHING-FANG YU, JI-HONG HONG and CHI-SHIUN CHIANG

In Vivo May 2020, 34 (3) 1141-1152; DOI: https://doi.org/10.21873/invivo.11886
You have access
Negative Effect of Immediate Sunitinib Interruption on Survival in Patients With Metastatic Renal Cell Carcinoma
RYO ISHIYAMA, HIROKI ISHIHARA, TSUNENORI KONDO, TOSHIO TAKAGI, KAZUHIKO YOSHIDA, JUNPEI IIZUKA, HIROHITO KOBAYASHI, MASAYOSHI OKUMI, HIDEKI ISHIDA and KAZUNARI TANABE

In Vivo November 2019, 33 (6) 2153-2160; DOI: https://doi.org/10.21873/invivo.11717
You have access
Isolated Central Nervous System Relapse in Two Patients with BCR–ABL-positive Acute Leukemia While Receiving a Next-generation Tyrosine Kinase Inhibitor
SUMIT GAUR, ALI-REZA TORABI and JAVIER CORRAL

In Vivo November 2014, 28 (6) 1149-1153;

Main menu

User menu

Search

tyrosine kinase inhibitor